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Abstract
Radiology is strongly depending on medical imaging
technology and consequently directing technological
progress. A novel technology can only be established,
however, if improved diagnostic accuracy inﬂuence on
therapeutic management and/or overall reduced cost can
be evidenced. It has been demonstrated recently that
Magnetic Resonance Imaging (MRI) and Positron
Emission Tomography (PET) can technologically be
integrated into one single hybrid system. Some scientiﬁc
arguments on the beneﬁts are obvious, e.g., that simul-
taneous imaging of morphological and functional infor-
mation will improve tissue characterization. However,
crossﬁre of questions still remains: What unmet radio-
logical needs are addressed by the novel system? What
level of hardware integration is reasonable, or would
software-based image co-registration be sufﬁcient? Will
MR/PET achieve higher diagnostic accuracy compared
to separate imaging? What is the added value compared
to other hybrid imaging modalities like PET/CT? And
ﬁnally, is the system economically reasonable and has the
potential to reduce overall costs for therapy planning and
monitoring? This article tries to highlight some perspec-
tives of applying an integrated MR/PET system for
simultaneous morphologic and functional imaging.
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Combining two or more imaging modalities into one
multi-modality machine is challenging. The imaging
systems have to perform without mutual interferences
while maintaining their full individual performance.
Furthermore, the available space for accommodating the
hardware from different scanners is often restricted.
Another challenge is that the software components have
to be integrated into one single analysis software package
enabling and advanced workﬂow in routine radiology. A
ﬁrst realization of a multi-modality clinical imaging
system is the combination of X-ray computed tomogra-
phy (CT) and positron emission tomography (PET) [1].
While at the beginning, PET/CT was critically viewed
and many skeptical clinicians asked about the diagnostic
value of such a system, PET/CT is now fully accepted
into the clinical diagnostic routine and has matured to an
important tool in the field of clinical oncology [2].
Instrumentation
In PET/CT, the two scanners are hard-wired and
implemented into a single gantry using one common bed,
which is traveling through the two scanners. Thus, a full
integration of PET and CT hardware, such as a common
detector technology, is not realized yet. The highly dif-
ferent properties of low-energy X-rays with a high ﬂux,
as used in CT, and the high-energy gamma rays in PET
disable the use of a single detector to collect radiation
from both imaging modalities. This technical limitation
does not only result in increased costs to provide twice
the imaging hardware, but does also disable simulta-
neous imaging. Thus, in PET/CT, the data are always
acquired sequentially, ﬁrst from CT and thereafter from
PET. This limitation restricts the overlay accuracy of the
two imaging data as well as the compensation of motion
artifacts between the relatively slow PET acquisition and
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tage of PET/CT, besides providing multi-parametric
morphological and functional information, is the feature
to use the CT image for PET attenuation correction. In
comparison to the conventional PET attenuation cor-
rection, where rotating
68Ge or
137Cs point or rod sources
were used to acquire a transmission scan, using the CT
information results in a reduction of scan time by nearly
a factor of two.
Driven since more than 10 years, mainly by the small
animal imaging research community, a new multi-
modality imaging device appears now on the horizon,
which is the combination of PET with magnetic reso-
nance imaging (MRI). Although to combine PET and
MRI is more challenging than combining PET/CT, MR/
PET might compensate some of the shortcomings of
PET/CT. This is feasible as the ultimate goal is to fully
integrate the PET detector technology into an MRI
gantry, enabling simultaneous PET and MRI data
acquisition to provide spatial and temporal accurate
correlated multi-parametric data. Simultaneous imaging
not only improves the diagnostic value of MR/PET, but
also enables respiratory or cardiac motion correction as
well as track gut or patient movement.
Conventional PET detectors are based on relatively
bulky photomultipliers (PMTs), which detect the scin-
tillation light. PMTs are very sensitive even to weak
magnetic ﬁelds and are therefore not suitable to be used
in a combined MR/PET scanner. In addition, its size
would steal too much space from the open magnet bore if
integrated within a MRI scanner. As an alternative, new
semiconductor-based light detectors, such as avalanche
photodiodes (APDs) are replacing PMTs in combined
MR/PET.
Initial animal MR/PET scanners [3–5] and very re-
cently a first human brain MR-PET [6] are based on this
new PET detector technology.
A high-resolution PET scanner prototype for brain
imaging entitled BrainPET
1, which is insensitive to
magnetic fields, is built to slip-fit into a 3 Tesla whole
MRI bore. This is the first human MR/PET scanner built
by a commercial supplier. Since the intention of this MR/
PET scanner is a feasibility study to explore future MR-
PET applications, it already enables initial studies with
patients. Since this prototype PET scanner is realized as
an insert, it can be removed from the MRI scanner so
that the 3 Tesla system can be used as standard imaging
device. Although this prototype MR-PET allows only
brain imaging with a standard MR bird cage coil, it
provides all imaging capabilities as a future fully inte-
grated whole-body MR/PET. Most importantly the PET
and MRI data can be acquired simultaneously allowing
not only a high-spatial overlay accuracy, but also an
excellent temporal co-registration. This is in sharp con-
trast to PET/CT and might enable MR-based PET image
motion correction for accurate abdominal or cardiac
imaging. Considering all the advantages of simultaneous
multi-parametric imaging and the much longer MR scan
time, compared to CT, a sequential MR/PET device
might not be very useful clinically.
The BrainPET uses PET block detectors-based APDs
to detect the scintillation light from the lutetium oxy-
orthosilicate (LSO) crystals. The prototype camera
achieves a 192 mm axial ﬁeld of view (FOV) and 355-mm
transaxial FOV of the PET scanner. The PET reveals a
spatial resolution of about 2.5–3 mm in the recon-
structed image, which is superior to other clinical PET
systems. Evaluation studies have shown, that both sys-
tems, the PET and MRI, maintain their full individual
imaging performance with minimal mutual interference
between the two scanners. The MR scanner even allows
the application of demanding sequences such as spec-
troscopy (MRS) or echo planar imaging (EPI), which is
used for functional MRI (fMRI). First applications of
the prototype demonstrated high resolution in phantom
studies and the feasibility of simultaneous MRI and PET
data acquisition in patients [6]. The image quality ob-
tained with simultaneous MR/PET is comparable to
stand-alone systems and allowed accurate co-registration
of morphologic and functional information (Fig. 1).
Co-registration vs. combination of MRI
and PET
The combination of anatomical and functional infor-
mation into one single image has been pursued for a long
time, and various strategies have been applied for co-
registration of PET or SPECT and MRI or CT images [1,
7]. On principle, PET quantification in the picomolar
range of various functional parameters (e.g., metabolism,
flow, receptor-ligand binding, enzyme activity, gene
expression) can be correctly correlated to normal and
pathologically altered anatomy, and additionally com-
plemented with dynamic information from functional
MR. Combining anatomic, functional, and metabolic
information of both modalities permits the complemen-
tary assessment of biological properties (Table 1).
Software fusion of PET and CT or MRI images suffer
from limitations: the imaging modalities usually are lo-
cated in different laboratories, the image properties, e.g.,
resolutions are different and suffer from distortion, im-
age translations and rotations, partial volume effects
cannot be compared, and dynamic changes cannot be
followed in an identiﬁed structure. The fusions of brain
images—which will be the main objective of this discus-
sion—is relatively easy owing to its rigid structure,
whereas especially in the abdomen or thorax an exact re-
location of the patient is difﬁcult and makes the align-
ment of images from different modalities uncertain. A
1BrainPET is a Works in Progress device.
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alignment of images and permits the combination of
morphology with multi-functional information from
PET, MRI, fMRI, and MRS. The ﬁrst simultaneous
MR/PET study demonstrates the feasibility of this ap-
proach and may justify some speculations on further
applications [6].
Potential applications of MR/PET in the brain
Integrated MR-PET is on the verge of being applied to
clinical neurosciences as it is already utilized in pre-
clinical research [4]. The combined system will extend
the impact of simultaneous imaging of morphology and
function as well as metabolism. Co-registration of MR
and PET images was successfully applied for detection
and staging of gliomas [8, 9] as well as for identification
of eloquent areas in the vicinity of tumors, which is
important for planning surgery [10]. Combined PET
and MRI information has gained a place in early
diagnosis of dementia and mild cognitive impairment
[11] and of degenerative disorders, e.g., cerebellar
atrophy, Huntington chorea. It was of special clinical
value in the detection of epileptic foci accessible for
surgery [12] and in the identification of metabolic
activity, transmitter concentration and enzyme expres-
sion in small brain structures [13]. In experimental focal
brain ischemia and ischemic stroke, co-registration of
regional values for cerebral blood flow, oxygen utiliza-
tion and glucose metabolism to early and late MRI
permitted the distinction of irreversibly damaged and
functionally impaired, but morphologically preserved,
i.e., penumbra tissue in the acute phase, a differentia-
tion valid for the selection of appropriate treatment
strategies [14].
These future applications of combined MR/PET will
gain new dimensions with the simultaneous MR and
PET procedures becoming possible with BrainPET.
Simultaneous data acquisition will allow the addition of
kinetic, functional, and metabolic information for real
time multi-parametric functional imaging:
– MRA will add the vascular origin of changes in
cerebral blood flow, oxygen consumption and metab-
olism in vascular diseases, including subarachnoid
hemorrhages.
– MRS will add additional metabolic information, e.g.,
lactate concentration, ATP, choline, N-acetyl-aspar-
tate, to regional metabolic data from PET (
15O2,
FDG, FLT) in stroke, gliomas, and degenerative
disorders.
– Perfusion (PWI) can be related to hypoxic markers
(
18F-MISO PET) and metabolic markers as lactate,
choline, N-acetyl-aspartate (MRS) in gliomas and
ischemia.
– DWI-PWI can be performed during PET measure-
ments of
15O2 and H2
15O for differentiation of
Fig. 1. MR (FLAIR sequence),
[
18F]FDG PET and fused images
of the brain acquired
simultaneously with an
integrated MR/PET system.
Acquisition time 15 min.
Table 1. Assessment of biological properties by MR and PET
MR PET
Morphology Flow (H2
15O)
Water diffusion capacity (DWI) Metabolism (
18F-FDG)
Vascular anatomy (MRA) Blood volume (C
15O)
Perfusion (PWI, DCE-MRI) Oxygen consumption (
15O)
Tissue metabolites (MRS) Hypoxia (
18F-MISO)
Functional activation (fMRI) Vascular permeability (labeled AA)
Cerebral fiber tracts (DTI) Nuclide acid synthesis (
18F-FLT)
Oxygen consumption (
17O) Transmitters (e.g.,
18F-DOPA)
Migration of cells (Fe labeling) Receptors (e.g., raclopride)
Enzymatic activity (e.g., MP4A)
Angiogenesis (e.g.,
18F-RGD)
Distribution and kinetics of tracers and drugs
(labeled compounds)
Enzymatic activity in transfected cells
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and irreversible tissue damage in ischemic stroke.
– Comparative activation studies with fMRI and H2
15O
(or FDG) PET will settle the discussion on the exact
localization of activation patterns (intravascular vs.
tissue signals).
– The effect of activation by specific tasks on transmitter
release or receptor binding can be analyzed by
combining fMRI with PET of, e.g., DOPA or raclo-
pride.
– Effects of drugs and of withdrawal (e.g., nicotine) on
task performance can be studied by fMRI and PET
receptor ligands (e.g.,
11C-raclopride).
The combination of MR and PET in the acquisition of
dynamic data will improve modeling for quantification
of metabolic values
– PWI could be used to determine flow-dependent
kinetic constants for compartmental analysis of PET
data (e.g., FDG, FLT).
– Perfusion can be assessed by PWI simultaneously with
metabolic and functional parameters from PET.
– The dynamics of distribution and the kinetics of
various tracers or drugs can be obtained in various
brain structures.
– A new MR tracer for oxygen utilizations (
17O) could
be validated on simultaneously recorded
15O utiliza-
tion by PET (O2 ﬁ H2O).
– Arterial spin labeling (ASL) MRI could be validated
by H2
15O-PET for measurement of CBF.
For complex studies of brain functions special combina-
tions of modalities or additional investigative procedures
may open new insights into the organization of the brain
and the changes in disease:
– Diffusion tensor tracking can be added to activation
studies and effects on transmitter release and receptor
occupancy as well as on metabolism in connected areas
can be analyzed as substrates of connectivity in
networks.
– Repetitive transcranial magnetic stimulation can be
used to activate or inhibit selected areas of the cortex,
and the effect on metabolism and the involvement of
transmitter systems can be analyzed.
– Deep brain stimulation is nowadays a means to
ameliorate neurological symptoms and improve
abnormal behavior [15]. The effect of this invasive
manipulation on metabolism and transmitter/receptor
interaction in defined regions together with the con-
necting fiber tracts can be evaluated.
An innovative experimental field which is opening up
with this new combined imaging modality is molecular
and cellular imaging.
– Angiogenesis is a fundamental process in various
physiologic and pathologic processes. Visualization,
quantification, and monitoring of angiogenesis are of
interest in various fields, including oncology and
cardiology. Molecules regulating angiogenesis include
growth factor receptors and integrins. Cyclic RGD
peptides bind to activated integrin amb3, and
18F-
galacto RGD [16] has been tested in humans with high
uptake in highly vascularized tumors. As an alterna-
tive approach labeled ligands to the vascular endothe-
lial growth factor receptor were applied. Combined
with dynamic contrast-enhanced MRI—yielding vas-
cular and extravascular volumes, vascular permeabil-
ity and perfusion—angiogenesis PET-markers will
permit the monitoring of angiogenetic and anti-
angiogenetic treatment [17].
– Targeted gene transfer by various vectors can be used
to express foreign enzymes in cells; this strategy can be
applied, e.g., to make malignant cells susceptible to
specific drugs, which are toxic only to those cells
expressing this enzyme. In an experimental glioma
model the efficacy of this treatment strategy with
transfer of Herpes virus thymidine kinase gene and
application of gancyclovir was demonstrated; preli-
minary clinical tests also showed some efficacy of this
treatment option [18]. The effect of this therapy can be
followed by multitracer PET and verified on MRI.
– Implantation of embryonic stem cells into striatum
lesioned by 6-OHDA injection in rats leads to prolif-
eration and differentiation of dopaminergic cells. This
could be demonstrated by co-registering MRI and
PET of the specific dopamine transporter ligands
11C-
2betacarbometoxy-3beta-(4fluorophenyl)tropane
(CFT) where CFT binding was restored in the region
of post-mortem documented TH-immunoreactive neu-
rons. The restored functional activity of these im-
planted cells was demonstrated by the response to
amphetamine causing increase in rCBV due to DA
release [19]. Simultaneous MR/PET can be used to
show the viability and differentiation of transplanted
cells and their effect on the neuronal networks.
– Cell replacement approaches are an innovative strat-
egy for treatment of various neurological disorders.
For the development of these approaches in animal
models it is essential to monitor the location and
follow the migration of grafted stem or progenitor
cells. Various strategies have been proposed for
labeling these cells with ultrasmall superparamagnetic
iron oxide particles and micronsized iron oxide parti-
cles [20]. In focal experimental ischemia labeled stem
cells migrated during 3 weeks from the contralateral
implantation site along the corpus callosum to the
ventricular walls and massively populated the border
zone of the damaged brain tissue on the lesioned
hemisphere. A combination of these MRI studies with
PET procedures could demonstrate the viability of the
cells as well as their integration into functional
networks. Monitoring cell viability and migration by
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might become also a qualifying step in strategies
relying on transplantation of fetal grafts, e.g., in
Parkinson’s disease.
Comparison of MR/PET and PET/CT for
body imaging
Potential clinical applications of MR/PET in body
imaging will include predominantly the ﬁelds of oncol-
ogy and cardiovascular diseases.
Although morphologic imaging is important, the
assessment of tissue aggressiveness or viability cannot be
based on pathoanatomic information alone. The intro-
duction of PET/CT has considerably improved oncologic
imaging by combining anatomical with functional
information concerning cell metabolism and receptor
density. More sensitive and speciﬁc diagnosis could be
achieved for different tumor entities enabling individu-
alized therapy planning, monitoring and evaluation of
recurrent disease. Current indications for PET/CT in-
clude, e.g., non-small cell lung cancer (NSCLC), esoph-
ageal cancer, colorectal cancer or lymphoma. As high-
resolution whole-body MRI has become feasible [21],
clinical studies compared to whole-body CT and PET/
CT have shown complementary advantages of MR and
PET [22, 23].
MR provides anatomical details with high soft tissue
contrast and a variety of functional information about
perfusion, diffusion, and metabolism. PET enables
assessment of metabolic abnormalities in mass lesions
and their changes early during therapy before changes in
tumor size can be measured. Improved spatial, contrast,
and temporal resolution of MR implies several advan-
tages of simultaneous MR/PET as compared sequential
PET/CT.
1. The superior soft tissue contrast of MR is in general
relevant for all types of soft tissue tumors regarding
detection, delineation, characterization, and staging.
However, CT is still more sensitive than MR in
revealing small lung nodules, bone and bone struc-
tures.
2. Dynamic MR studies can yield functional tissue
parameters for quantitation of perfusion without
additional radiation exposure, and PET studies can be
simultaneously performed. The resulting images
represent the tissue and the vascular component of the
tumor.
3. The complementary morphological and metabolic
data can be relevant for defining biopsy targets,
particularly by separating areas of active tumor from
inflammation, fibrosis or necrosis. For this, addi-
tional information obtained with MRS and/or special
tracers, as
11C- or
18F-choline in prostate cancer,
18F-L-thymidine in germ cell tumors and with
11C-methionine and
18F-L-thymidine in brain tumors,
or by imaging of angiogenesis (
18F-RGD).
4. Combined morphological and metabolic imaging is
important for the evaluation of early treatment re-
sponse. Metabolic information assessed by FDG,
MET, or FLT is more sensitive to detect therapy-in-
duced metabolic and necrotic tissue damage. Addi-
tional high-resolution morphologic information may
be potentially helpful in the planning of subsequent
surgery and radiotherapy.
5. Fast MR sequences can improve the image quality of
PET by providing kinetic information of breathing or
cardiac activity and thereby minimizing artifacts in
PET images, e.g., by (respiratory and cardiac gating).
Cardiac gating is of especial importance for imaging of
the myocardium depicting pathological changes, e.g.,
infarcts and scars. Changes in blood flow and metab-
olism and possible neovascularization can be detected
within the infarct zone by PET applying, e.g.,
18F-
RGD as tracer for integrine activation. As a pre-
requisite,however,precisemotioncorrectionandexact
morphologic-metabolic co-registration are important.
6. MRI causes no additional radiation exposure, which
is of importance especially in dynamic contrast-en-
hanced studies and repeated examinations. This is of
particular importance for follow-up of younger indi-
viduals after curative treatment, e.g., testicular tumors
or malignant melanoma.
Regarding the screening for metastases, MR is superior in
the detection of brain, liver, and bone marrow metastases
and PET is important for characterizing lymph nodes and
soft tissue masses [22, 24]. MRI provide more anatomical
details than CT, e.g., in the head and neck region, where
the differentiation of closed anatomical structures like
mucosa, submucosal tissues, salivary glands, muscles,
lymphnodes,andbloodvesselsisindispensibleformaking
correct diagnoses and therapy plans. MR is in general
preferable for abdominal and pelvic imaging. Detailed
MR/PET information about anatomy and metabolism
will enable better tumors staging of several tumor entities,
e.g., liver, cervical, prostate, urinary bladder or rectal
cancer. In thoracic tumors, however, PET/CT will still be
preferable because CT is the imaging modality of choice
for the examination of the lung.
Regarding the detection of bone metastases, FDG-
PET/CT can be false negative in case of small metastases.
Minor tracer uptake may not be visualized because of
physiological FDG tracer uptake of normal bone mar-
row and CT may be negative as changes in bone archi-
tecture may not yet be present. MRI on the other hand
images the bone marrow itself and has consequently been
proven to be even more sensitive than conventional bone
scintigraphy [25].
Another major diagnostic problem in oncology is the
differentiation of therapy-related scar tissue from recur-
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radiochemotherapy. Suspicious tissue in the pelvis can be
differentiated from normal anatomical structures, while
FDG-PET enables information about their probable
pathologic tracer uptake.
Non-oncologic applications of MR/PET include the
assessment of cardiovascular diseases. High-resolution
MRI and PET of the beating heart and pulsating arteries
will be feasible. MR-information about cardiac and
respiratory motion can be used for pro- or retrospective
MR-gating of the PET data acquisition. Application of
whole-body MR/PET in the ﬁeld of cardiovascular
imaging will include the evaluation of myocardial per-
fusion, viability plaque imaging and assessment of
inﬂammatory disorders, e.g., aortitis. Whole-body MR-
Angiography can be combined with cardiac MR.
It is important to mention, however, that whole-
body MR/PET applications will require a reliable
method for MR-based photon attenuation correction,
which is challenging and still under development until
now [26, 27].
Conclusions
There is no doubt that PET/CT will remain an important
diagnostic instrument in clinical routine, but further
scientiﬁc and clinical progress can be anticipated by hy-
brid MR/PET imaging. The integrated MR/PET will
deﬁnitely serve in research for the exploration of
molecular mechanisms in healthy individuals as well as in
complex disease. If it can be shown that a combined
reading of PET and MRI improves diagnostic accuracy
or efﬁcacy of treatments via better monitoring, it may
become part of medical guidelines. However, it needs to
be proven that the integration of both modalities is
economically superior to two individual systems.
The main economic argument for the integration is
that PET and MR are both complex and time-con-
suming examinations and subsequent imaging is con-
sequently cumbersome for the patient and laborious
regarding the workﬂow. Thus the costs for two separate
diagnoses in both modalities pose an immense burden
to the patients and the healthcare providers. As true
simultaneous PET and MR imaging become feasible,
the overall scan time can signiﬁcantly be reduced
compared to sequential scanning. Simultaneous MR/
PET imaging will also cut down the time needed for
visualization and interpretation of separate and/or fused
images. These savings in cost support the aforemen-
tioned requirement from healthcare systems of a higher
quality at lower cost and might open the path for MR/
PET into clinical routine.
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